多模态人工智能数字病理生物标志物预测根治性前列腺切除术后生化复发患者转移:NRG/RTOG试验开发与验证
本研究开发并验证了一种基于数字病理的多模态人工智能(MMAI)模型,用于预测根治性前列腺切除术后生化复发(BCR)患者接受挽救治疗后的远处转移(DM)。模型在NRG/RTOG 9601和0534试验的533例患者中验证,中位随访9.3年,MMAI评分与DM显著相关(sHR=2.17每标准差,95%CI 1.65-2.85,p<0.001),10年时依AUC为0.74,优于临床列线图的0.68。高风险组10年DM发生率为25%,低风险组为8.8%;高风险组接受激素治疗联合挽救放疗相比单纯挽救放疗的10年DM绝对降低为21%,低风险组为2.5%。
要点
- MMAI模型可个体化预测术后BCR患者远处转移风险。
- MMAI评分与DM显著相关且独立于临床变量和治疗。
- 高风险组从激素治疗联合挽救放疗中绝对获益更大。
核心结论
- MMAI模型可为术后BCR患者提供个体化风险估计,可能支持挽救治疗的共享决策。
研究设计与样本
- 使用前列腺组织病理图像特征和临床变量训练MMAI模型预测DM,临床变量包括病理分级组、病理T分期、挽救放疗前PSA水平、年龄和手术切缘。
- 锁定模型在NRG/RTOG 9601和0534试验的533例接受挽救放疗±激素治疗的患者中验证,采用Cox回归和时间依赖AUC。
主要发现
- 中位随访9.3年,MMAI评分与DM显著相关(sHR=2.17每标准差,95%CI 1.65-2.85,p<0.001)。
- 调整临床变量和治疗后,MMAI评分仍为独立预后因素。
- MMAI的10年时间依赖AUC为0.74,临床列线图为0.68。
- 二分类风险分组显示,MMAI高风险组10年DM发生率为25%,低风险组为8.8%。
- 高风险组接受激素治疗联合挽救放疗相比单纯挽救放疗的10年DM绝对降低为21%,低风险组为2.5%。
关键数值与推荐
- MMAI评分每增加1个标准差,DM风险增加(sHR=2.17,95%CI 1.65-2.85,p<0.001)。
- 10年时间依赖AUC:MMAI为0.74,临床列线图为0.68。
- 10年DM发生率:MMAI高风险组25%,低风险组8.8%。
- 10年DM绝对降低(激素治疗+挽救放疗 vs 单纯挽救放疗):高风险组21%,低风险组2.5%。
临床怎么用
- MMAI模型可用于术后BCR患者接受挽救治疗前的风险分层,辅助共享决策。
- 高风险患者可能从激素治疗联合挽救放疗中获得更大绝对获益。
局限性
- 使用了归档的试验队列。
- 外部验证和前瞻性验证正在进行中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Biochemical recurrence (BCR) after radical prostatectomy (RP) is a heterogeneous disease state in prostate cancer with multiple treatment options. Improved risk stratification could enable more personalized decision-making. We developed and validated a digital pathology-based multimodal artificial intelligence (MMAI) model to predict outcomes in post-RP BCR patients undergoing salvage therapy. METHODS: An MMAI model was trained to predict distant metastasis (DM) using prostate histopathology image features and clinical variables (pathologic grade group, pathologic T stage, prostate-specific antigen level before salvage radiotherapy [SRT], age, and surgical margin). The locked model was validated in 533 patients from NRG/RTOG 9601 and 0534 treated with SRT ± hormone therapy (HT), using Cox regression and time-dependent area under the receiver operating characteristic curve. KEY FINDINGS AND LIMITATIONS: With a median follow-up of 9.3 yrs, MMAI score was significantly associated with DM (subdistribution hazard ratio = 2.17 per standard deviation [95% confidence interval 1.65-2.85]; p < 0.001) and remained independently prognostic after adjusting for clinical variables and treatment. The 10-yr time-dependent area under the receiver operating characteristic curve for MMAI was 0.74 compared with 0.68 for a clinical nomogram. Binary risk categorization demonstrated higher 10-yr DM incidence in the MMAI high-risk (25%) than in the low-risk (8.8%) group. The absolute reduction in 10-yr DM incidence with HT plus SRT versus SRT alone was 21% in the high-risk group versus 2.5% in the low-risk group. Limitations include the use of archived trial cohorts. CONCLUSIONS AND CLINICAL IMPLICATIONS: The post-RP MMAI model provides individualized risk estimates after SRT ± HT and may support shared decision-making about salvage treatment. External and prospective validation are ongoing.
引用
- Morgan TM, Ren Y, Tang S, et al. Development and Validation of a Multimodal Artificial Intelligence-derived Digital Pathology-based Biomarker Predicting Metastasis Among Patients with Biochemical Recurrence After Radical Prostatectomy in NRG/RTOG Trials. Eur Urol. 2025. PMID: 41436315. doi:10.1016/j.eururo.2025.12.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。